Treatment of Basal Cell Carcinoma of Skin in Metastatic Disease

Metastatic basal cell carcinoma (mBCC) represents the most advanced stage of this skin malignancy, where disease has spread beyond the primary site. This scenario requires specific systemic management distinct from localised or locally advanced disease.

Clinical scenario: Advanced BCC encompasses both locally advanced BCC (laBCC) and metastatic BCC (mBCC). When disease reaches the metastatic stage, treatment goals shift toward systemic disease control and quality-of-life preservation.

Treatment Approach

For patients with metastatic basal cell carcinoma, a platinum-based chemotherapy regimen may be considered as part of the management approach — with additional options available depending on individual patient circumstances.

The complete regimen, sequencing, and supportive care framework are detailed in the full structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

Advanced BCC includes locally advanced BCC (laBCC) and metastatic BCC (mBCC).
Chemotherapy might be considered for laBCC and mBCC in patients who are not responsive or have progressed after HHI and PD-1 inhibitors, alone or in combination with radiotherapy.
Most patients with widespread metastases received platinum-based chemotherapies.
An early involvement of the interdisciplinary best supportive care team is recommended for symptomatic patients with locally advanced and metastatic BCC.

DOI: 10.1016/j.ejca.2023.113254

View source ↗